Drugs and Devices

Effectiveness of abaloparatide in patients with osteoporosis

Subcutaneous abaloparatide reduces the risk of new vertebral and nonvertebral fractures over 18 months in patients with osteoporosis, according to a study in JAMA. Read more


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares